As part of a study, they interviewed people with rare autoimmune diseases: Franziska Bütow, Dr. Hümmert and Professor Trebst (from left to right). Copyright: Karin Kaiser / MHH.
As part of a study, they interviewed people with rare autoimmune diseases: Franziska Bütow, Dr. Hümmert and Professor Trebst ( from left to right ). Copyright: Karin Kaiser / MHH. In times of crisis, it is advantageous for people with rare diseases to receive care in highly specialized centers. This is underlined by an MHH study. It shows that the people with the autoimmune diseases NMOSD and MOGAD cared for there came through the COVID 19 pandemic well. For people with chronic diseases, the COVID-19 pandemic was particularly challenging: many were worried and uncertain about the risk of infection, vaccination, and continuing their (immunosuppressive) therapy. A team from the Department of Neurology with Clinical Neurophysiology at Hannover Medical School (MHH) wanted to know how patients with the rare chronic autoimmune diseases neuromyelitis optica spectrum disease (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) got through the pandemic.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
